NBRV - Nabriva Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5158.34M
Enterprise Value 3100.09M
Trailing P/E N/A
Forward P/E 1-2.34
PEG Ratio (5 yr expected) 1-0.02
Price/Sales (ttm)41.58
Price/Book (mrq)2.53
Enterprise Value/Revenue 326.28
Enterprise Value/EBITDA 6-1.13

Trading Information

Stock Price History

Beta (3Y Monthly) 2.67
52-Week Change 3-14.89%
S&P500 52-Week Change 31.31%
52 Week High 33.2700
52 Week Low 31.1200
50-Day Moving Average 32.3387
200-Day Moving Average 32.3966

Share Statistics

Avg Vol (3 month) 3748.69k
Avg Vol (10 day) 32.16M
Shares Outstanding 572.78M
Float 55.21M
% Held by Insiders 10.61%
% Held by Institutions 153.09%
Shares Short (Jul 15, 2019) 41.19M
Short Ratio (Jul 15, 2019) 42.2
Short % of Float (Jul 15, 2019) 41.65%
Short % of Shares Outstanding (Jul 15, 2019) 41.64%
Shares Short (prior month Jun 14, 2019) 42.12M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 21/10
Last Split Date 3Jun 26, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-2,329.49%

Management Effectiveness

Return on Assets (ttm)-54.23%
Return on Equity (ttm)-163.79%

Income Statement

Revenue (ttm)3.81M
Revenue Per Share (ttm)0.06
Quarterly Revenue Growth (yoy)-77.40%
Gross Profit (ttm)-40.58M
EBITDA -88.2M
Net Income Avi to Common (ttm)-121.66M
Diluted EPS (ttm)-2.0710
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)91.27M
Total Cash Per Share (mrq)1.26
Total Debt (mrq)25.92M
Total Debt/Equity (mrq)43.13
Current Ratio (mrq)5.55
Book Value Per Share (mrq)0.84

Cash Flow Statement

Operating Cash Flow (ttm)-77.01M
Levered Free Cash Flow (ttm)-43.53M